Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Regeneron Pharmaceuticals recently completed a study titled ‘Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study.’ The study aimed to estimate the incidence of Retinal Vasculitis (RV) and RV plus Intraocular Inflammation (IOI) in patients treated with aflibercept 2mg injections, providing crucial insights into the safety profile of this widely used therapy.
Intervention/Treatment: The study focused on aflibercept 2mg, marketed as Eylea®, administered intravitreally. This drug is used to treat various retinal conditions, and the study sought to understand its association with RV in real-world settings.
Study Design: This was an observational, retrospective cohort study. It did not involve any study-specific interventions, focusing instead on analyzing existing data from patients aged 18 and older who received aflibercept 2mg during the study period.
Study Timeline: The study was first submitted on July 8, 2025, and the last update was submitted on October 9, 2025. These dates mark the timeline of data collection and analysis, culminating in the study’s completion.
Market Implications: The completion of this study could influence Regeneron’s stock performance by providing reassurance about the safety of Eylea®, potentially boosting investor confidence. In the competitive landscape of retinal treatments, demonstrating a favorable safety profile is crucial for maintaining market share and investor interest.
The study is completed, and further details are available on the ClinicalTrials portal.